FLT3 ITD

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
FLT3 ITD OR FLT3 TKD MUTATION OR NRAS EXON 2-3 MUTATION OR PTPN11 Mutation OR KRAS Exon 2-3 Mutation	Selumetinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12553 In a preclinical genomic and functional study of pediatric acute lymphoblastic leukemia (n = 81 paired diagnosis–relapse samples), recurrent RAS-pathway mutations involving NRAS (exons 2-3), KRAS (exo… (full text at CIViC) PMID 24316979 · Wong et al., 2014 · Open in CIViC	civic
Acute Myeloid Leukemia42
FLT3 ITD	(prognostic)	Prognostic	A	Supports Poor Outcome	3	accepted	EID190 Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD. PMID 24801015 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Acute Lymphoblastic Leukemia1

FLT3 ITD OR FLT3 TKD MUTATION OR NRAS EXON 2-3 MUTATION OR PTPN11 Mutation OR KRAS Exon 2-3 Mutation

Selumetinib

Predictive

Supports Sensitivity Response

submitted

EID12553

In a preclinical genomic and functional study of pediatric acute lymphoblastic leukemia (n = 81 paired diagnosis–relapse samples), recurrent RAS-pathway mutations involving NRAS (exons 2-3), KRAS (exo… (full text at CIViC)

PMID 24316979 · Wong et al., 2014 · Open in CIViC

civic

Acute Myeloid Leukemia42

FLT3 ITD

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID190

Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD.

PMID 24801015 ·

Acute Promyelocytic Leukemia2
FLT3 ITD	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID1109 In a study of 53 APL patients treated with combination ATRA/anthracycline chemotherapy, patients with the FLT3 ITD mutation (n=10) had higher rates of relapse (30% vs. 2.5%), lower rates of remission … (full text at CIViC) PMID 21461300 · Hong et al., 2011 · Open in CIViC	civic
FLT3 ITD	Anthracycline Antineoplastic Antibiotic + TretinoinCombination	Predictive	B	Supports Resistance	4	accepted	EID1112 In a study of 171 APL patients treated with combination ATRA/anthracycline chemotherapy, FLT3 ITD mutations (n=35) were associated with lower 3-year OS compared to the FLT3 ITD-negative group (62% vs.… (full text at CIViC) PMID 24981688 · Lucena-Araujo et al., 2014 · Open in CIViC	civic

Acute Promyelocytic Leukemia2

FLT3 ITD

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID1109

In a study of 53 APL patients treated with combination ATRA/anthracycline chemotherapy, patients with the FLT3 ITD mutation (n=10) had higher rates of relapse (30% vs. 2.5%), lower rates of remission … (full text at CIViC)

PMID 21461300 · Hong et al., 2011 · Open in CIViC

civic

FLT3 ITD

Anthracycline Antineoplastic Antibiotic + TretinoinCombination

Predictive

Supports Resistance

accepted

EID1112

In a study of 171 APL patients treated with combination ATRA/anthracycline chemotherapy, FLT3 ITD mutations (n=35) were associated with lower 3-year OS compared to the FLT3 ITD-negative group (62% vs.… (full text at CIViC)

PMID 24981688 · Lucena-Araujo et al., 2014 · Open in CIViC

civic

Leukemia4
FLT3 ITD	Sorafenib	Predictive	D	Does Not Support Sensitivity Response	5	rejected	EID7372 In a preclinical trial, MV4-11 leukemic cell lines with the FLT3-ITD mutation and RS4;11 leukemic cell lines with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib,… (full text at CIViC) PMID 21482694 · Gozgit et al., 2011 · Open in CIViC	civic
FLT3 ITD	Sorafenib	Predictive	D	Supports Sensitivity Response	5	rejected	EID7373 In a preclinical trial, MV4-11 leukemic cell lines with the FLT3-ITD mutation and RS4;11 leukemic cell lines with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib,… (full text at CIViC) PMID 21482694 · Gozgit et al., 2011 · Open in CIViC	civic
FLT3 ITD	Sorafenib + SunitinibSubstitutes	Predictive	D	Supports Sensitivity Response	4	accepted	EID7382 In a preclinical trial, the leukemic cell line MV4-11 with the FLT3-ITD mutation and the leukemic cell line RS4;11 with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) pona… (full text at CIViC) PMID 21482694 · Gozgit et al., 2011 · Open in CIViC	civic
FLT3 ITD	Sunitinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7374 In a preclinical trial, MV4-11 leukemic cell lines with the FLT3-ITD mutation and RS4;11 leukemic cell lines with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib,… (full text at CIViC) PMID 21482694 · Gozgit et al., 2011 · Open in CIViC	civic

Leukemia4

FLT3 ITD

Sorafenib

Predictive

Does Not Support Sensitivity Response

rejected

EID7372

In a preclinical trial, MV4-11 leukemic cell lines with the FLT3-ITD mutation and RS4;11 leukemic cell lines with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib,… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

civic

FLT3 ITD

Sorafenib

Predictive

Supports Sensitivity Response

rejected

EID7373

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

civic

FLT3 ITD

Sorafenib + SunitinibSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID7382

In a preclinical trial, the leukemic cell line MV4-11 with the FLT3-ITD mutation and the leukemic cell line RS4;11 with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) pona… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

civic

FLT3 ITD

Sunitinib

Predictive

Supports Sensitivity Response

submitted

EID7374

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

civic

Malignant Neoplasm1
FLT3 ITD AND ( FLT3 D835V OR FLT3 D835Y OR FLT3 Y842C OR FLT3 F691L OR FLT3 Y842H )	Sorafenib	Predictive	D	Supports Resistance	3	submitted	EID12629 In an in-vitro study using an in vitro saturation mutagenesis assay, residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. These mutations… (full text at CIViC) PMID 22504184 · Smith et al., 2012 · Open in CIViC	civic

Malignant Neoplasm1

FLT3 ITD AND ( FLT3 D835V OR FLT3 D835Y OR FLT3 Y842C OR FLT3 F691L OR FLT3 Y842H )

Sorafenib

Predictive

Supports Resistance

submitted

EID12629

In an in-vitro study using an in vitro saturation mutagenesis assay, residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. These mutations… (full text at CIViC)

PMID 22504184 · Smith et al., 2012 · Open in CIViC

civic

Evidence by cancer (52 items)

Clinical significance (0)